GRCL (Gracell Biotechnologies) קצב צמיחת רווח למניה בשנה הנוכחית

Through its integration with AstraZeneca, Gracell Biotechnologies (GRCL) has retained its key scientific staff, preventing brain drain. This is bolstered by the company's own cGMP facilities in the US and China, which guarantee autonomous drug production. The business relies on breakthroughs in CAR-T therapy, remaining insulated from economic cycles. The annual earnings per share trajectory illustrates these successes, and the parameter has stabilized at 0.00.

Gracell Biotechnologies (GRCL) innovations in affordable cell therapy require colossal expenditures, which directly impacts yield dynamics. By analyzing the year-over-year (YoY) change in net income per share, an investor can observe the growth or decline rates of EPS relative to the previous year. This indicator measures the efficiency of business capitalization, allowing for the determination of the fair value of shares for this high-risk biotechnological asset.